We are no longer providing equity research on Abiomed . We provide broad coverage of more than 1,800 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
Abiomed reported strong fiscal second-quarter ..... largely consistent with our expectations. Abiomed remains on track to reach our full-year ..... continues to grow, which supports our view of Abiomed 's positive moat trend. We think there
By Andy Batts : Abiomed ( ABMD ), a leading provider of novel percutaneous cardiac assist devices ..... last four years. ABMD Revenue Per Share ( TTM ) data by YCharts Abiomed 's Impella range of heart pumps has enormous growth potential in
Abiomed , Inc. ( ABMD ) F2Q2014 Results Earnings Call November ..... ladies and gentlemen, and welcome to the Abiomed Second Quarter 2014 Earnings Conference ..... thanks everyone for joining us for the Abiomed second quarter fiscal 2014 conference
the difference between analysts' expectations and reported results. The figures are provided by Thomson Reuters I/B/E/S. Company Name Ticker Qtr Industry Curr EPS Est EPS Act Diff EPS Rev Est Rev Act Diff Rev ABIOMED INC Q2 MEDICA
Abiomed ( ABMD ): FQ2 EPS of $0.03 in-line. Revenue of $44.3M (+19% Y/Y) beats by $0.55M . ( PR ) Post your comment!
ABMD , AUXL , AVA , CHK , CLH , CNP , CSTE , CWH , DUK , DVN , END , EZCH , GEO , GGS , HCLP , HFC , HSNI , HSP , HUM , KELYA , LAMR
Abiomed reported fiscal first-quarter performance ..... variance from quarter to quarter, we think Abiomed can still reach our full-year projections ..... nascent stage of the acute VAD market that Abiomed is still pioneering, we do not think the
unlikely to reach commercialization before 2017. Even though it will be several years before the PHP product is marketable, it nonetheless provides Thoratec with important entree to the acute VAD niche that is currently dominated by Abiomed .
On Wednesday, Abiomed ABMD released preliminary fourth-quarter ..... our positive moat trend rating for Abiomed . Although we do not believe the firm ..... yet, momentum continues to build for Abiomed with the U.S. release of Impella